1
|
Tsukijima M, Teramoto A, Kojima A, Yamamuro O, Tamaki T, Fujita H. A position-adaptive noise-reduction method using a deep denoising filter bank for dedicated breast positron emission tomography images. Phys Eng Sci Med 2024; 47:73-85. [PMID: 37870728 DOI: 10.1007/s13246-023-01343-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Accepted: 10/02/2023] [Indexed: 10/24/2023]
Abstract
Dedicated breast positron emission tomography (db-PET) is more sensitive than whole-body positron emission tomography and is thus expected to detect early stage breast cancer and determine treatment efficacy. However, it is challenging to decrease the sensitivity of the chest wall side at the edge of the detector, resulting in a relative increase in noise and a decrease in detectability. Longer acquisition times and injection of larger amounts of tracer improve image quality but increase the burden on the patient. Therefore, this study aimed to improve image quality via reconstruction with shorter acquisition time data using deep learning, which has recently been widely used as a noise reduction technique. In our proposed method, a multi-adaptive denoising filter bank structure was introduced by training the training data separately for each detector area because the noise characteristics of db-PET images vary at different locations. Input and ideal images were reconstructed based on 1- and 7-min collection data, respectively, using list mode data. The deep learning model used residual learning with an encoder-decoder structure. The image quality of the proposed method was superior to that of existing noise reduction filters such as Gaussian filters and nonlocal mean filters. Furthermore, there was no significant difference between the maximum standardized uptake values before and after filtering using the proposed method. Taken together, the proposed method is useful as a noise reduction filter for db-PET images, as it can reduce the patient burden, scan time, and radiotracer amount in db-PET examinations.
Collapse
Affiliation(s)
- Masahiro Tsukijima
- Imaging Diagnostic Technology Department, East Nagoya Imaging Diagnosis Center, 3-4-26 Jiyugaoka, Chikusa-ku, Nagoya, Aichi, Japan
- Graduate School of Health Sciences, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, Japan
| | | | - Akihiro Kojima
- Nagoya PET Imaging Center, 1-162 Hokke, Nakagawa-ku, Nagoya, Aichi, Japan
| | - Osamu Yamamuro
- Imaging Diagnostic Technology Department, East Nagoya Imaging Diagnosis Center, 3-4-26 Jiyugaoka, Chikusa-ku, Nagoya, Aichi, Japan
| | - Tsuneo Tamaki
- Imaging Diagnostic Technology Department, East Nagoya Imaging Diagnosis Center, 3-4-26 Jiyugaoka, Chikusa-ku, Nagoya, Aichi, Japan
| | - Hiroshi Fujita
- Faculty of Engineering, Gifu University, 1-1 Yanagido, Gifu, Japan
| |
Collapse
|
2
|
Abstract
Breast-specific positron imaging systems provide higher sensitivity than whole-body PET for breast cancer detection. The clinical applications for breast-specific positron imaging are similar to breast MRI including preoperative local staging and neoadjuvant therapy response assessment. Breast-specific positron imaging may be an alternative for patients who cannot undergo breast MRI. Further research is needed in expanding the field-of-view for posterior breast lesions, increasing biopsy capability, and reducing radiation dose. Efforts are also necessary for developing appropriate use criteria, increasing availability, and advancing insurance coverage.
Collapse
Affiliation(s)
- Amy M Fowler
- Department of Radiology, University of Wisconsin School of Medicine and Public Health, 600 Highland Avenue, Madison, WI 53792-3252, USA; Department of Medical Physics, University of Wisconsin-Madison; University of Wisconsin Carbone Cancer Center, Madison, WI, USA.
| | - Kanae K Miyake
- Department of Advanced Medical Imaging Research, Graduate School of Medicine Kyoto University, Kyoto, Japan
| | - Yuji Nakamoto
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine Kyoto University, Kyoto, Japan
| |
Collapse
|
3
|
Patel MM, Adrada BE, Fowler AM, Rauch GM. Molecular Breast Imaging and Positron Emission Mammography. PET Clin 2023; 18:487-501. [PMID: 37258343 DOI: 10.1016/j.cpet.2023.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
There is growing interest in application of functional imaging modalities for adjunct breast imaging due to their unique ability to evaluate molecular/pathophysiologic changes, not visible by standard anatomic breast imaging. This has led to increased use of nuclear medicine dedicated breast-specific single photon and coincidence imaging systems for multiple indications, such as supplemental screening, staging of newly diagnosed breast cancer, evaluation of response to neoadjuvant treatment, diagnosis of local disease recurrence in the breast, and problem solving. Studies show that these systems maybe especially useful for specific subsets of patients, not well served by available anatomic breast imaging modalities.
Collapse
Affiliation(s)
- Miral M Patel
- Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, CPB5.3208, Houston, TX 77030, USA.
| | - Beatriz Elena Adrada
- Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, CPB5.3208, Houston, TX 77030, USA
| | - Amy M Fowler
- Department of Radiology, Section of Breast Imaging and Intervention, University of Wisconsin - Madison, 600 Highland Avenue, Madison, WI 53792-3252, USA; Department of Medical Physics, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, 600 Highland Avenue, Madison, WI 53792-3252, USA
| | - Gaiane M Rauch
- Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1473, Houston, TX 77030, USA; Department of Breast Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Unit 1473, Houston, TX 77030, USA
| |
Collapse
|
4
|
Yuge S, Miyake KK, Ishimori T, Kataoka M, Matsumoto Y, Torii M, Yakami M, Isoda H, Takakura K, Morita S, Takada M, Toi M, Nakamoto Y. Performance of dedicated breast PET in breast cancer screening: comparison with digital mammography plus digital breast tomosynthesis and ultrasound. Ann Nucl Med 2023; 37:479-493. [PMID: 37280410 DOI: 10.1007/s12149-023-01846-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2023] [Accepted: 05/11/2023] [Indexed: 06/08/2023]
Abstract
OBJECTIVE To compare the diagnostic performance of dedicated breast positron emission tomography (dbPET) in breast cancer screening with digital mammography plus digital breast tomosynthesis (DM-DBT) and breast ultrasound (US). METHODS Women who participated in opportunistic whole-body PET/computed tomography cancer screening programs with breast examinations using dbPET, DM-DBT, and US between 2016-2020, whose results were determined pathologically or by follow-up for at least 1 year, were included. DbPET, DM-DBT, and US assessments were classified into four diagnostic categories: A (no abnormality), B (mild abnormality), C (need for follow-up), and D (recommend further examination). Category D was defined as screening positive. Each modality's recall rate, sensitivity, specificity, and positive predictive value (PPV) were calculated per examination to evaluate their diagnostic performance for breast cancer. RESULTS Out of 2156 screenings, 18 breast cancer cases were diagnosed during the follow-up period (10 invasive cancers and eight ductal carcinomas in situ [DCIS]). The recall rates for dbPET, DM-DBT, and US were 17.8%, 19.2%, and 9.4%, respectively. The recall rate of dbPET was highest in the first year and subsequently decreased to 11.4%. dbPET, DM-DBT, and US had sensitivities of 72.2%, 88.9%, and 83.3%; specificities of 82.6%, 81.4%, and 91.2%; and PPVs of 3.4%, 3.9%, and 7.4%, respectively. The sensitivities of dbPET, DM-DBT, and US for invasive cancers were 90%, 100%, and 90%, respectively. There were no significant differences between the modalities. One case of dbPET-false-negative invasive cancer was identified in retrospect. DbPET had 50% sensitivity for DCIS, while that of both DM-DBT and US was 75%. Furthermore, the specificity of dbPET in the first year was the lowest among all periods, and modalities increased over the years to 88.7%. The specificity of dbPET was significantly higher than that of DM-DBT (p < 0.01) in the last 3 years. CONCLUSIONS DbPET had a compatible sensitivity to DM-DBT and breast US for invasive breast cancer. The specificity of dbPET was improved and became higher than that of DM-DBT. DbPET may be a feasible screening modality.
Collapse
Affiliation(s)
- Shunsuke Yuge
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Kanae K Miyake
- Department of Advanced Medical Imaging Research, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-Cho, Sakyo-Ku, Kyoto, 606-8507, Japan.
| | - Takayoshi Ishimori
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masako Kataoka
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yoshiaki Matsumoto
- Preemptive Medicine and Lifestyle-Related Disease Research Center, Kyoto University Hospital, Kyoto, Japan
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masae Torii
- Department of Breast Surgery, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan
| | - Masahiro Yakami
- Preemptive Medicine and Lifestyle-Related Disease Research Center, Kyoto University Hospital, Kyoto, Japan
| | - Hiroyoshi Isoda
- Preemptive Medicine and Lifestyle-Related Disease Research Center, Kyoto University Hospital, Kyoto, Japan
| | - Kyoko Takakura
- Preemptive Medicine and Lifestyle-Related Disease Research Center, Kyoto University Hospital, Kyoto, Japan
| | - Satoshi Morita
- Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masahiro Takada
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Masakazu Toi
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yuji Nakamoto
- Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
5
|
Okamoto M, Hasegawa T, Oda K, Miyatake H, Kikuchi K, Inoue Y, Satoh Y, Inaoka Y, Kawamoto M, Shima K, Kanbayashi K, Yoshii M, Kanno T, Wagatsuma K, Hashimoto M. Dedicated phantom tools using traceable 68Ge/ 68Ga point-like sources for dedicated-breast PET and positron emission mammography scanners. Radiol Phys Technol 2023; 16:49-56. [PMID: 36622563 DOI: 10.1007/s12194-022-00692-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Revised: 11/24/2022] [Accepted: 11/25/2022] [Indexed: 01/10/2023]
Abstract
Since the early 2000s, many types of positron emission tomography (PET) scanners dedicated to breast imaging for the diagnosis of breast cancer have been introduced. However, conventional performance evaluation methods developed for whole-body PET scanners cannot be used for such devices. In this study, we developed phantom tools for evaluating the quantitative accuracy of positron emission mammography (PEM) and dedicated-breast PET (dbPET) scanners using novel traceable point-like 68Ge/68 Ga sources. The PEM phantom consisted of an acrylic cube (100 × 100 × 40 mm) and three point-like sources. The dbPET phantom comprised an acrylic cylinder (ø100 × 100 mm) and five point-like sources. These phantoms were used for evaluating the fundamental responses of clinical PEM and dbPET scanners to point-like inputs in a medium. The results showed that reasonable recovery values were obtained based on region-of-interest analyses of the reconstructed images. The developed phantoms using traceable 68Ge/68 Ga point-like sources were useful for evaluating the physical characteristics of PEM and dbPET scanners. Thus, they offer a practical, reliable, and universal measurement scheme for evaluating various types of PET scanners using common sets of sealed sources.
Collapse
Affiliation(s)
- Mio Okamoto
- Juntendo University Hospital, 3-1-3, Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan.,Kitasato University Graduate School of Medical Sciences, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0373, Japan
| | - Tomoyuki Hasegawa
- Kitasato University Graduate School of Medical Sciences, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0373, Japan. .,School of Allied Health Sciences, Kitasato University, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0373, Japan.
| | - Keiichi Oda
- Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2, Sakae-cho, Itabashi-ku, Tokyo, Japan
| | - Hiroki Miyatake
- Department of Radiology, Kitasato University Hospital, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0375, Japan
| | - Kei Kikuchi
- Department of Radiology, Kitasato University Hospital, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0375, Japan
| | - Yusuke Inoue
- Department of Diagnostic Radiology, Kitasato University School of Medicine, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0374, Japan
| | - Yoko Satoh
- Yamanashi PET Imaging Clinic, 3046-2, Shimokato, Chuo, Yamanashi, 409-3821, Japan
| | - Yuichi Inaoka
- Shimadzu Corporation, 1, Nishinokyo Kuwabara-cho, Nakagyo-ku, Kyoto, 604-8511, Japan
| | - Masami Kawamoto
- Advanced Medical Center, Shonan Kamakura General Hospital, 1370-1, Okamoto, Kamakura, Kanagawa, 247-8533, Japan
| | - Koji Shima
- Division of Radiology, Yuai Clinic, 1-6-2, Shinyokohama, Kouhokuku, Yokohama, Kanagawa, 223-0059, Japan
| | - Kenji Kanbayashi
- Division of Radiology, Yuai Clinic, 1-6-2, Shinyokohama, Kouhokuku, Yokohama, Kanagawa, 223-0059, Japan
| | - Miho Yoshii
- Division of Radiology, Yuai Clinic, 1-6-2, Shinyokohama, Kouhokuku, Yokohama, Kanagawa, 223-0059, Japan
| | - Tomoyuki Kanno
- Division of Radiology, Yuai Clinic, 1-6-2, Shinyokohama, Kouhokuku, Yokohama, Kanagawa, 223-0059, Japan
| | - Kei Wagatsuma
- Kitasato University Graduate School of Medical Sciences, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0373, Japan.,School of Allied Health Sciences, Kitasato University, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0373, Japan.,Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2, Sakae-cho, Itabashi-ku, Tokyo, Japan
| | - Masatoshi Hashimoto
- Kitasato University Graduate School of Medical Sciences, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0373, Japan.,School of Allied Health Sciences, Kitasato University, 1-15-1, Kitasato, Minamiku, Sagamihara, Kanagawa, 252-0373, Japan
| |
Collapse
|
6
|
Kataoka M, Iima M, Miyake KK, Matsumoto Y. Multiparametric imaging of breast cancer: An update of current applications. Diagn Interv Imaging 2022; 103:574-583. [DOI: 10.1016/j.diii.2022.10.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 10/26/2022] [Indexed: 11/21/2022]
|
7
|
Breast-Specific Gamma Imaging: An Added Value in the Diagnosis of Breast Cancer, a Systematic Review. Cancers (Basel) 2022; 14:cancers14194619. [PMID: 36230540 PMCID: PMC9559460 DOI: 10.3390/cancers14194619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Revised: 09/19/2022] [Accepted: 09/20/2022] [Indexed: 11/23/2022] Open
Abstract
Simple Summary Breast-specific gamma imaging represents an emergent instrument for breast cancer detection. We selected on Medline articles published from 1995 to 2022 that compare various imaging modalities with breast-specific gamma imaging. The aim of this paper was to assess if this imaging method is a more valuable choice in detecting breast malignant lesions compared to morphological counterparts such mammography, ultrasound, and magnetic resonance imaging in terms of specificity, sensibility and positive and negative predictive value. At the cost of a major radiology burden, breast-specific gamma imaging is more specific, with a sensibility comparable to magnetic resonance imaging and higher than ultrasonography and mammography. Abstract Purpose: Breast cancer is the most common solid tumor and the second highest cause of death in the United States. Detection and diagnosis of breast tumors includes various imaging modalities, such as mammography (MMG), ultrasound (US), and contrast-enhancement MRI. Breast-specific gamma imaging (BSGI) is an emerging tool, whereas morphological imaging has the disadvantage of a higher absorbed dose. Our aim was to assess if this imaging method is a more valuable choice in detecting breast malignant lesions compared to morphological counterparts. Methods: research on Medline from 1995 to June 2022 was conducted. Studies that compared at least one anatomical imaging modality with BSGI were screened and assessed through QUADAS2 for risk of bias and applicability concerns assessment. Sensitivity, specificity, positive and negative predictive value (PPV and NPV) were reported. Results: A total of 15 studies compared BSGI with MMG, US, and MRI. BSGI sensitivity was similar to MRI, but specificity was higher. Specificity was always higher than MMG and US. BSGI had higher PPV and NPV. When used for the evaluation of a suspected breast lesion, the overall sensitivity was better than the examined overall sensitivity when BSGI was excluded. Risk of bias and applicability concerns domain showed mainly low risk of bias. Conclusion: BSGI is a valuable imaging modality with similar sensitivity to MRI but higher specificity, although at the cost of higher radiation burden.
Collapse
|
8
|
Miller B, Chalfant H, Thomas A, Wellberg E, Henson C, McNally MW, Grizzle WE, Jain A, McNally LR. Diabetes, Obesity, and Inflammation: Impact on Clinical and Radiographic Features of Breast Cancer. Int J Mol Sci 2021; 22:2757. [PMID: 33803201 PMCID: PMC7963150 DOI: 10.3390/ijms22052757] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2021] [Revised: 03/01/2021] [Accepted: 03/04/2021] [Indexed: 02/06/2023] Open
Abstract
Obesity, diabetes, and inflammation increase the risk of breast cancer, the most common malignancy in women. One of the mainstays of breast cancer treatment and improving outcomes is early detection through imaging-based screening. There may be a role for individualized imaging strategies for patients with certain co-morbidities. Herein, we review the literature regarding the accuracy of conventional imaging modalities in obese and diabetic women, the potential role of anti-inflammatory agents to improve detection, and the novel molecular imaging techniques that may have a role for breast cancer screening in these patients. We demonstrate that with conventional imaging modalities, increased sensitivity often comes with a loss of specificity, resulting in unnecessary biopsies and overtreatment. Obese women have body size limitations that impair image quality, and diabetes increases the risk for dense breast tis-sue. Increased density is known to obscure the diagnosis of cancer on routine screening mammography. Novel molecu-lar imaging agents with targets such as estrogen receptor, human epidermal growth factor receptor 2 (HER2), pyrimi-dine analogues, and ligand-targeted receptor probes, among others, have potential to reduce false positive results. They can also improve detection rates with increased resolution and inform therapeutic decision making. These emerg-ing imaging techniques promise to improve breast cancer diagnosis in obese patients with diabetes who have dense breasts, but more work is needed to validate their clinical application.
Collapse
Affiliation(s)
- Braden Miller
- Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; (B.M.); (H.C.)
| | - Hunter Chalfant
- Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; (B.M.); (H.C.)
| | - Alexandra Thomas
- Department of Internal Medicine, Wake Forest University School of Medicine, Wake Forest University, Winston-Salem, NC 27157, USA;
| | - Elizabeth Wellberg
- Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73105, USA;
| | - Christina Henson
- Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73105, USA;
| | | | - William E. Grizzle
- Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA;
| | - Ajay Jain
- Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; (B.M.); (H.C.)
- Stephenson Cancer Center, Oklahoma City, OK 73104, USA;
| | - Lacey R. McNally
- Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA; (B.M.); (H.C.)
- Stephenson Cancer Center, Oklahoma City, OK 73104, USA;
| |
Collapse
|
9
|
Satoh Y, Kawamoto M, Kubota K, Murakami K, Hosono M, Senda M, Sasaki M, Momose T, Ito K, Okamura T, Oda K, Kuge Y, Sakurai M, Tateishi U, Fujibayashi Y, Magata Y, Yoshida T, Waki A, Kato K, Hashimoto T, Uchiyama M, Kinuya S, Higashi T, Magata Y, Machitori A, Maruno H, Minamimoto R, Yoshinaga K. Clinical practice guidelines for high-resolution breast PET, 2019 edition. Ann Nucl Med 2021; 35:406-414. [PMID: 33492646 PMCID: PMC7902575 DOI: 10.1007/s12149-021-01582-y] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 12/28/2020] [Indexed: 02/08/2023]
Abstract
Breast positron emission tomography (PET) has had insurance coverage when performed with conventional whole-body PET in Japan since 2013. Together with whole-body PET, accurate examination of breast cancer and diagnosis of metastatic disease are possible, and are expected to contribute significantly to its treatment planning. To facilitate a safer, smoother, and more appropriate examination, the Japanese Society of Nuclear Medicine published the first edition of practice guidelines for high-resolution breast PET in 2013. Subsequently, new types of breast PET have been developed and their clinical usefulness clarified. Therefore, the guidelines for breast PET were revised in 2019. This article updates readers as to what is new in the second edition. This edition supports two different types of breast PET depending on the placement of the detector: the opposite-type (positron emission mammography; PEM) and the ring-shaped type (dedicated breast PET; dbPET), providing an overview of these scanners and appropriate imaging methods, their clinical applications, and future prospects. The name "dedicated breast PET" from the first edition is widely used to refer to ring-shaped type breast PET. In this edition, "breast PET" has been defined as a term that refers to both opposite- and ring-shaped devices. Up-to-date breast PET practice guidelines would help provide useful information for evidence-based breast imaging.
Collapse
Affiliation(s)
- Yoko Satoh
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan. .,Yamanashi PET Imaging Clinic, Shimokato 3046-2, Chuo City, Yamanashi Prefecture, 409-3821, Japan.
| | - Masami Kawamoto
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | | | - Koji Murakami
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Makoto Hosono
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Michio Senda
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Masayuki Sasaki
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Toshimitsu Momose
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Kengo Ito
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Terue Okamura
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Keiichi Oda
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Yuji Kuge
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Minoru Sakurai
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Ukihide Tateishi
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Yasuhisa Fujibayashi
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Yasuhiro Magata
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Takeshi Yoshida
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Atsuo Waki
- PET Nuclear Medicine Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Katsuhiko Kato
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Teisuke Hashimoto
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Mayuki Uchiyama
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Seigo Kinuya
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Tatsuya Higashi
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Yasuhiro Magata
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Akihiro Machitori
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Hirotaka Maruno
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Ryogo Minamimoto
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| | - Keiichiro Yoshinaga
- Health Insurance Committee, Japanese Society of Nuclear Medicine, Tokyo, Japan
| |
Collapse
|
10
|
Satoh Y, Motosugi U, Imai M, Omiya Y, Onishi H. Evaluation of image quality at the detector's edge of dedicated breast positron emission tomography. EJNMMI Phys 2021; 8:5. [PMID: 33462645 PMCID: PMC7813900 DOI: 10.1186/s40658-020-00351-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2020] [Accepted: 12/22/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Using phantoms and clinical studies in prone hanging breast imaging, we assessed the image quality of a commercially available dedicated breast PET (dbPET) at the detector's edge, where mammary glands near the chest wall are located. These are compared to supine PET/CT breast images of the same clinical subjects. METHODS A breast phantom with four spheres (16-, 10-, 7.5-, and 5-mm diameter) was filled with 18F-fluorodeoxyglucose solution (sphere-to-background activity concentration ratio, 8:1). The spheres occupied five different positions from the top edge to the centre of the detector and were scanned for 5 min in each position. Reconstructed images were visually evaluated, and the contrast-to-noise ratio (CNR), contrast recovery coefficient (CRC) for all spheres, and coefficient of variation of the background (CVB) were calculated. Subsequently, clinical images obtained with standard supine PET/CT and prone dbPET were retrospectively analysed. Tumour-to-background ratios (TBRs) between breast cancer near the chest wall (close to the detector's edge; peripheral group) and at other locations (non-peripheral group) were compared. The TBR of each lesion was compared between dbPET and PET/CT. RESULTS Closer to the detector's edge, the CNR and CRC of all spheres decreased while the CVB increased in the phantom study. The disadvantages of this placement were visually confirmed. Regarding clinical images, TBR of dbPET was significantly higher than that of PET/CT in both the peripheral (12.38 ± 6.41 vs 6.73 ± 3.5, p = 0.0006) and non-peripheral (12.44 ± 5.94 vs 7.71 ± 7.1, p = 0.0183) groups. There was no significant difference in TBR of dbPET between the peripheral and non-peripheral groups. CONCLUSION The phantom study revealed poorer image quality at < 2-cm distance from the detector's edge than at other more central parts. In clinical studies, however, the visibility of breast lesions with dbPET was the same regardless of the lesion position, and it was higher than that in PET/CT. dbPET has a great potential for detecting breast lesions near the chest wall if they are at least 2 cm from the edge of the FOV, even in young women with small breasts.
Collapse
Affiliation(s)
- Yoko Satoh
- Yamanashi PET Imaging Clinic, Shimokato 3046-2, Chuo City, Yamanashi Prefecture, 409-3821, Japan. .,Department of Radiology, University of Yamanashi, Chuo City, Yamanashi Prefecture, Japan.
| | - Utaroh Motosugi
- Department of Radiology, Kofu-kyoritsu Hospital, Kofu City, Yamanashi Prefecture, Japan
| | - Masamichi Imai
- Yamanashi PET Imaging Clinic, Shimokato 3046-2, Chuo City, Yamanashi Prefecture, 409-3821, Japan
| | - Yoshie Omiya
- Department of Radiology, University of Yamanashi, Chuo City, Yamanashi Prefecture, Japan
| | - Hiroshi Onishi
- Department of Radiology, University of Yamanashi, Chuo City, Yamanashi Prefecture, Japan
| |
Collapse
|
11
|
Keshavarz K, Jafari M, Lotfi F, Bastani P, Salesi M, Gheisari F, Rezaei Hemami M. Positron Emission Mammography (PEM) in the diagnosis of breast cancer: A systematic review and economic evaluation. Med J Islam Repub Iran 2020; 34:100. [PMID: 33315994 PMCID: PMC7722955 DOI: 10.34171/mjiri.34.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2019] [Indexed: 12/09/2022] Open
Abstract
Background: Positron Emission Mammography (PEM) is an imaging technique which is increasing focuses on imaging the chest instead of imaging the whole body. The aim of this study was to conduct a systematic review of the clinical efficacy and coste-ffectiveness of PEM technology, as compared with PET, as a diagnostic method used for breast cancer patients.
Methods: The present study was a Health Technology Assessment (HTA), which was conducted via a systematic review of clinical efficacy and cost-effectiveness of the methods based on domestic evidence. To evaluate the efficacy of the PEM diagnostic method, as compared with PET, we used efficacy indices, including Sensitivity, Specificity, Accuracy, PPV, and NPV. The required data were collected through a meta-analysis of studies published in electronic databases from 1990 to 2016. In addition, direct costs in both methods were estimated and finally, a cost-effectiveness analysis was performed using the results of the study. Also, a one-way sensitivity analysis was performed to examine the effects of parameters’ uncertainty in the model. In this study, we used STATA software to integrate the results of studies with similar parameters.
Results: A total of 722 cases (N) were obtained from the five final studies. The results of the meta-analysis performed on the collected data showed that the two methods were identical in terms of the Specificity and PPV parameters. However, as to Sensitivity, NPV, and Accuracy parameters, the PEM method was superior to the PET for diagnosis of primary breast cancer. The total cost of using PEM and PET was $1737385.7 and $1940903.5, respectively, and the cost of a one-time scan (cost per unit) using PEM and PET devices was $86.82 and $157.63, respectively. As compared with the PET method, the use of the PEM diagnostic method for diagnosis of breast cancer was cost-effective in terms of all the five studied parameters (it was definitely cost-effective for four parameters and was also considered as cost-effective for another index, since ICER was below the threshold).
Conclusion: The results showed that the use of PEM technology for the diagnosis of primary breast cancer is more cost-effective than PET technology; thus, due to the wide range of PET technology in different fields, it is recommended that this method should be used in other areas of priority.
Collapse
Affiliation(s)
- Khosro Keshavarz
- Health Human Resources Research Center, School of Management and Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mojtaba Jafari
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Farhad Lotfi
- Health Human Resources Research Center, School of Management and Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Peivand Bastani
- Health Human Resources Research Center, School of Management and Medical Informatics, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Mahmood Salesi
- Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
| | - Farshid Gheisari
- Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.,Ionizing and Non-Ionizing Radiation Protection Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran
| | | |
Collapse
|
12
|
Characterisation of MRI Indeterminate Breast Lesions Using Dedicated Breast PET and Prone FDG PET-CT in Patients with Breast Cancer—A Proof-of-Concept Study. J Pers Med 2020; 10:jpm10040148. [PMID: 32992995 PMCID: PMC7712852 DOI: 10.3390/jpm10040148] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Revised: 09/17/2020] [Accepted: 09/21/2020] [Indexed: 01/18/2023] Open
Abstract
Magnetic resonance imaging (MRI) in patients with breast cancer to assess extent of disease or multifocal disease can demonstrate indeterminate lesions requiring second-look ultrasound and ultrasound or MRI-guided biopsies. Prone positron emission tomography-computed tomography (PET-CT) is a dedicated acquisition performed with a breast-supporting device on a standard PET-CT scanner. The MAMmography with Molecular Imaging (MAMMI, Oncovision, Valencia, Spain) PET system (PET-MAMMI) is a true tomographic ring scanner for the breast. We investigated if PET-MAMMI and prone PET-CT were able to characterise these MRI- indeterminate lesions further. A total of 10 patients with breast cancer and indeterminate lesions on breast MRI were included. Patients underwent prone PET-MAMMI and prone PET-CT after injection of FDG subsequently on the same day. Patients then resumed their normal pathway, with the clinicians blinded to the results of the PET-MAMMI and prone PET-CT. Of the MRI-indeterminate lesions, eight were histopathologically proven to be malignant and two were benign. PET-MAMMI and prone PET-CT only were able to demonstrate increased FDG uptake in 1/8 and 0/8 of the MRI-indeterminate malignant lesions, respectively. Of the MRI-indeterminate benign lesions, both PET-MAMMI and prone PET-CT demonstrated avidity in 1/2 of these lesions. Our findings do not support the use of PET-MAMMI to characterise indeterminate breast MRI lesions requiring a second look ultrasound.
Collapse
|
13
|
Abstract
Screening for breast cancer reduces breast cancer-related mortality and earlier detection facilitates less aggressive treatment. Unfortunately, current screening modalities are imperfect, suffering from limited sensitivity and high false-positive rates. Novel techniques in the field of breast imaging may soon play a role in breast cancer screening: digital breast tomosynthesis, contrast material-enhanced spectral mammography, US (automated three-dimensional breast US, transmission tomography, elastography, optoacoustic imaging), MRI (abbreviated and ultrafast, diffusion-weighted imaging), and molecular breast imaging. Artificial intelligence and radiomics have the potential to further improve screening strategies. Furthermore, nonimaging-based screening tests such as liquid biopsy and breathing tests may transform the screening landscape. © RSNA, 2020 Online supplemental material is available for this article.
Collapse
Affiliation(s)
- Ritse M Mann
- From the Department of Radiology, Nuclear Medicine and Anatomy, Radboud University Medical Center, Geert Grooteplein 10, PO Box 9101, 6500 HB, Nijmegen, the Netherlands (R.M.M.); Department of Radiology, the Netherlands Cancer Institute, Amsterdam, the Netherlands (R.M.M.); Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Conn (R.H.); Department of Radiology, Northeastern Ohio Medical University, Rootstown, Ohio (R.G.B.); Southwoods Imaging, Youngstown, Ohio (R.G.B.); Department of Radiology, New York University Langone School of Medicine, New York, NY (L.M.); and Department of Radiology, New York University Grossman School of Medicine, Center for Advanced Imaging Innovation and Research, Laura and Isaac Perlmutter Cancer Center, New York, NY (L.M.)
| | - Regina Hooley
- From the Department of Radiology, Nuclear Medicine and Anatomy, Radboud University Medical Center, Geert Grooteplein 10, PO Box 9101, 6500 HB, Nijmegen, the Netherlands (R.M.M.); Department of Radiology, the Netherlands Cancer Institute, Amsterdam, the Netherlands (R.M.M.); Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Conn (R.H.); Department of Radiology, Northeastern Ohio Medical University, Rootstown, Ohio (R.G.B.); Southwoods Imaging, Youngstown, Ohio (R.G.B.); Department of Radiology, New York University Langone School of Medicine, New York, NY (L.M.); and Department of Radiology, New York University Grossman School of Medicine, Center for Advanced Imaging Innovation and Research, Laura and Isaac Perlmutter Cancer Center, New York, NY (L.M.)
| | - Richard G Barr
- From the Department of Radiology, Nuclear Medicine and Anatomy, Radboud University Medical Center, Geert Grooteplein 10, PO Box 9101, 6500 HB, Nijmegen, the Netherlands (R.M.M.); Department of Radiology, the Netherlands Cancer Institute, Amsterdam, the Netherlands (R.M.M.); Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Conn (R.H.); Department of Radiology, Northeastern Ohio Medical University, Rootstown, Ohio (R.G.B.); Southwoods Imaging, Youngstown, Ohio (R.G.B.); Department of Radiology, New York University Langone School of Medicine, New York, NY (L.M.); and Department of Radiology, New York University Grossman School of Medicine, Center for Advanced Imaging Innovation and Research, Laura and Isaac Perlmutter Cancer Center, New York, NY (L.M.)
| | - Linda Moy
- From the Department of Radiology, Nuclear Medicine and Anatomy, Radboud University Medical Center, Geert Grooteplein 10, PO Box 9101, 6500 HB, Nijmegen, the Netherlands (R.M.M.); Department of Radiology, the Netherlands Cancer Institute, Amsterdam, the Netherlands (R.M.M.); Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Conn (R.H.); Department of Radiology, Northeastern Ohio Medical University, Rootstown, Ohio (R.G.B.); Southwoods Imaging, Youngstown, Ohio (R.G.B.); Department of Radiology, New York University Langone School of Medicine, New York, NY (L.M.); and Department of Radiology, New York University Grossman School of Medicine, Center for Advanced Imaging Innovation and Research, Laura and Isaac Perlmutter Cancer Center, New York, NY (L.M.)
| |
Collapse
|
14
|
Iranmakani S, Mortezazadeh T, Sajadian F, Ghaziani MF, Ghafari A, Khezerloo D, Musa AE. A review of various modalities in breast imaging: technical aspects and clinical outcomes. THE EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE 2020. [DOI: 10.1186/s43055-020-00175-5] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Abstract
Background
Nowadays, breast cancer is the second cause of death after cardiovascular diseases. In general, about one out of eight women (about 12%) suffer from this disease during their life in the USA and European countries. If breast cancer is detected at an early stage, its survival rate will be very high. Several methods have been introduced to diagnose breast cancer with their clinical advantages and disadvantages.
Main text
In this review, various methods of breast imaging have been introduced. Furthermore, the sensitivity and specificity of each of these methods have been investigated. For each of the imaging methods, articles that were relevant to the past 10 years were selected through electronic search engines, and then the most relevant papers were selected. Finally, about 40 articles were studied and their results were categorized and presented in the form of a report as follows. Various breast cancer imaging techniques were extracted as follows: mammography, contrast-enhanced mammography, digital tomosynthesis, sonography, sonoelastography, magnetic resonance imaging, magnetic elastography, diffusion-weighted imaging, magnetic spectroscopy, nuclear medicine, optical imaging, and microwave imaging.
Conclusion
The choice of these methods depends on the patient’s state and stage, the age of the individual and the density of the breast tissue. Hybrid imaging techniques appear to be an acceptable way to improve detection of breast cancer. This review article can be useful in choosing the right method for imaging in people suspected of breast cancer.
Collapse
|
15
|
Satoh Y, Sekine T, Omiya Y, Onishi H, Motosugi U. Reduction of the fluorine-18-labeled fluorodeoxyglucose dose for clinically dedicated breast positron emission tomography. EJNMMI Phys 2019; 6:21. [PMID: 31784863 PMCID: PMC6884607 DOI: 10.1186/s40658-019-0256-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Accepted: 10/09/2019] [Indexed: 02/06/2023] Open
Abstract
PURPOSE To determine the clinically acceptable level of reduction in the injected fluorine-18 (18F)-labeled fluorodeoxyglucose (18F-FDG) dose in dedicated breast positron emission tomography (dbPET). METHODS A breast phantom with four spheres exhibiting various diameters (5, 7.5, 10, and 16 mm), a background 18F-FDG radioactivity of 2.28 kBq/mL, and a sphere-to-background radioactivity ratio of 8:1 was used. True dose-reduced dbPET images were obtained by data acquisition for 20 min in list mode at multiple time points over 7 h of radioactive decay. Simulated dose-reduced images were generated by reconstruction with a portion of the list mode acquisition data. True and simulated dose-reduced images were visually and quantitatively compared. On the basis of the phantom study, dbPET images for 32 breasts of 28 women with abnormal uptake were generated after simulated reduction of the injected 18F-FDG doses; these images were compared with those acquired using current clinical doses. RESULTS There were no qualitative differences between true and simulated dose-reduced phantom images. The phantom study revealed that the minimal required dose was 12.5% for the detection of 5-mm spheres and 25% for precise semi-quantification of FDG in the spheres. The 7-min reconstruction with a 100% dose was defined as the reference for the clinical study. The image quality and lesion conspicuity were clinically acceptable for the 25% dose images. Lesion detectability on the 12.5% dose images was maintained despite image quality degradation. CONCLUSIONS In summary, 25% of the standard 18F-FDG dose for dbPET can provide a clinically acceptable image quality, while 12.5% of the standard dose results in acceptable quality in terms of lesion detection when lesions are located at a sufficient distance from the edge of the dbPET detector.
Collapse
Affiliation(s)
- Yoko Satoh
- Yamanashi PET Imaging Clinic, Shimokato 3046-2, Chuo City, Yamanashi Prefecture, 409-3821, Japan. .,Department of Radiology, University of Yamanashi, Chuo City, Yamanashi Prefecture, Japan.
| | - Tetsuro Sekine
- Department of Radiology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan
| | - Yoshie Omiya
- Department of Radiology, University of Yamanashi, Chuo City, Yamanashi Prefecture, Japan
| | - Hiroshi Onishi
- Department of Radiology, University of Yamanashi, Chuo City, Yamanashi Prefecture, Japan
| | - Utaroh Motosugi
- Department of Radiology, University of Yamanashi, Chuo City, Yamanashi Prefecture, Japan
| |
Collapse
|
16
|
Satoh Y, Motosugi U, Imai M, Onishi H. Comparison of dedicated breast positron emission tomography and whole-body positron emission tomography/computed tomography images: a common phantom study. Ann Nucl Med 2019; 34:119-127. [PMID: 31768819 DOI: 10.1007/s12149-019-01422-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Accepted: 11/14/2019] [Indexed: 12/13/2022]
Abstract
OBJECTIVE High-resolution dedicated breast positron emission tomography (dbPET) can visualize breast cancer more clearly than whole-body PET/computed tomography (CT). In Japan, the combined use of dbPET and whole-body PET/CT is necessary in indications for health insurance. Although several clinical studies have compared both devices, a physical evaluation by the phantom test has not been reported. The aim of this study was to compare the ability of ring-shaped dbPET and whole-body PET/CT using a common phantom with reference to the Japanese guideline for the oncology 18F-fluorodeoxyglucose (FDG)-PET/CT data acquisition protocol. METHODS A cylindrical breast phantom with four spheres of different diameters (16, 10, 7.5, and 5 mm) filled an FDG solution at sphere-to-background radioactivity ratios (SBRs) of 2:1, 4:1, and 8:1 was prepared. Images were then acquired by whole-body PET/CT and subsequently by dbPET. The reconstructed images were visually evaluated and the coefficient of variation and uniformity of the background (CVbackground and SDΔSUVmean), percentages of contrast and background variability (%QH,5mm and %N5mm), and their ratio (%QH,5mm/N5mm), and relative recovery coefficient were compared with the standards defined in the protocol for whole-body PET/CT. RESULTS The parameters were calculated at an SBR of 8:1, which was the only SBR in which a 5-mm sphere was visible on both devices. The standards were defined as < 10% for CVbackground, ≤ 0.025 for SDΔSUVmean, < 5.6% for %N5mm, > 2.8 for %QH,5mm/N5mm, and > 0.38 for the relative recovery coefficient of the smallest sphere (10 mm in diameter) in the protocol for whole-body PET/CT (the %QH,5mm was not determined for that protocol); the respective values were 6.14%, 0.024, 4.55%, 3.66, and 0.33 for dbPET and 2.21%, 0.021, 3.11%, 1.72, and 0.18 for PET/CT. The QH,5mm was 16.67% for dbPET and 5.34% for PET/CT. The human images also showed higher lesion-to-background contrast on dbPET than on PET/CT despite the noisier background observed with dbPET. CONCLUSION The common phantom study showed that the background was noisier and that the contrast was much higher in the dbPET image than in the PET/CT image. The acquisition protocol and standards for dbPET will need to be different from those used for whole-body PET/CT.
Collapse
Affiliation(s)
- Yoko Satoh
- Yamanashi PET Imaging Clinic, Shimokato 3046-2, Chuo, Yamanashi, 409-3821, Japan. .,Department of Radiology, University of Yamanashi, Chuo, Yamanashi, Japan.
| | - Utaroh Motosugi
- Department of Radiology, University of Yamanashi, Chuo, Yamanashi, Japan
| | - Masamichi Imai
- Yamanashi PET Imaging Clinic, Shimokato 3046-2, Chuo, Yamanashi, 409-3821, Japan
| | - Hiroshi Onishi
- Department of Radiology, University of Yamanashi, Chuo, Yamanashi, Japan
| |
Collapse
|
17
|
Molecular Imaging in Breast Cancer. Nucl Med Mol Imaging 2019; 53:313-319. [PMID: 31723360 DOI: 10.1007/s13139-019-00614-w] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 08/26/2019] [Accepted: 09/10/2019] [Indexed: 02/07/2023] Open
Abstract
Breast cancer (BC) is the most common cancer among females with more than 2 million new cases diagnosed worldwide in 2018. Although the prognosis in the majority of cases in the early stages combined with appropriate treatment is positive, there are still about 30% of patients who will develop locoregional diseases and distant metastases. Molecular imaging is very important in the diagnosis, staging, follow-up, and radiotherapy planning. Additionally, it is useful in characterizing lesions, prognosis, and therapy response in BC patients. Nuclear medicine imaging modalities (SPECT and PET) are of indispensable importance in diagnosis (positron emission mammography), staging (sentinel lymph node detection), and follow-up with18F-FDG and tumor characterization. Among many available PET tracers, the most commonly used are 18F-FLT, 18F-FES, 18F-FDHT, 64Cu DOTA trastuzumab (bevacizumab), 68Ga-PSMA, 68Ga-RM2 (gastrin-releasing peptide receptor), 18F-fluorooctreotide (SSTR), and 68Ga-TRAP (RGD)-3αvβ3-integrin. Molecular imaging helps in evaluation of tumor heterogeneity, allowing a shift from one-size-fits-all-approach to era of personalized medicine and precision oncology.
Collapse
|
18
|
Advanced approaches to imaging primary breast cancer: an update. Clin Transl Imaging 2019. [DOI: 10.1007/s40336-019-00346-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
19
|
Satoh Y, Motosugi U, Omiya Y, Onishi H. Unexpected Abnormal Uptake in the Breasts at Dedicated Breast PET: Incidentally Detected Small Cancers or Nonmalignant Features? AJR Am J Roentgenol 2019; 212:443-449. [DOI: 10.2214/ajr.18.20066] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Affiliation(s)
- Yoko Satoh
- Yamanashi PET Imaging Clinic, Shimokato 3046-2, Chuo City, Yamanashi, 409-3821, Japan
- Department of Radiology, University of Yamanashi, Chuo City, Yamanashi, Japan
| | - Utaroh Motosugi
- Department of Radiology, University of Yamanashi, Chuo City, Yamanashi, Japan
| | - Yoshie Omiya
- Department of Radiology, University of Yamanashi, Chuo City, Yamanashi, Japan
| | - Hiroshi Onishi
- Department of Radiology, University of Yamanashi, Chuo City, Yamanashi, Japan
| |
Collapse
|
20
|
Narayanan D, Berg WA. Dedicated Breast Gamma Camera Imaging and Breast PET: Current Status and Future Directions. PET Clin 2018; 13:363-381. [PMID: 30100076 DOI: 10.1016/j.cpet.2018.02.008] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Recent advances in nuclear medicine instrumentation have led to the emergence of improved molecular imaging techniques to image breast cancer: dedicated gamma cameras using γ-emitting 99mTc-sestamibi and breast-specific PET cameras using 18F-fluorodeoxyglucose. This article focuses on the current role of such approaches in the clinical setting including diagnosis, assessing local extent of disease, monitoring response to therapy, and, for gamma camera imaging, possible supplemental screening in women with dense breasts. Barriers to clinical adoption and technologies and radiotracers under development are also discussed.
Collapse
Affiliation(s)
- Deepa Narayanan
- National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20850, USA.
| | - Wendie A Berg
- Department of Radiology, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, 300 Halket Street, Pittsburgh, PA 15213
| |
Collapse
|
21
|
Narayanan D, Berg WA. Use of Breast-Specific PET Scanners and Comparison with MR Imaging. Magn Reson Imaging Clin N Am 2018; 26:265-272. [PMID: 29622131 DOI: 10.1016/j.mric.2017.12.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The goals of this article are to discuss the role of breast-specific PET imaging of women with breast cancer, compare the clinical performance of positron emission mammography (PEM) and MR imaging for current indications, and provide recommendations for when women should undergo PEM instead of breast MR imaging.
Collapse
Affiliation(s)
- Deepa Narayanan
- SBIR Development Center, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20850, USA.
| | - Wendie A Berg
- Department of Radiology, University of Pittsburgh School of Medicine, Magee-Womens Hospital of UPMC, 300 Halket Street, Pittsburgh, PA 15213, USA
| |
Collapse
|
22
|
Sah BR, Ghafoor S, Burger IA, Ter Voert EEGW, Sekine T, Delso G, Huellner M, Dedes KJ, Boss A, Veit-Haibach P. Feasibility of 18F-FDG Dose Reductions in Breast Cancer PET/MRI. J Nucl Med 2018; 59:1817-1822. [PMID: 29880506 DOI: 10.2967/jnumed.118.209007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Accepted: 04/27/2018] [Indexed: 12/16/2022] Open
Abstract
The goal of this study was to determine the level of clinically acceptable 18F-FDG dose reduction in time-of-flight PET/MRI in patients with breast cancer. Methods: Twenty-six consecutive women with histologically proven breast cancer were analyzed (median age, 51 y; range, 34-83 y). Simulated dose-reduced PET images were generated by unlisting the list-mode data on PET/MRI. The acquired 20-min PET frame was reconstructed in 5 ways: a reconstruction of the first 2 min with 3 iterations and 28 subsets for reference, and reconstructions simulating 100%, 20%, 10%, and 5% of the original dose. General image quality and artifacts, image sharpness, image noise, and lesion detectability were analyzed using a 4-point scale. Qualitative parameters were compared using the nonparametric Friedman test for multiple samples and the Wilcoxon signed-rank test for paired samples. Different groups of independent samples were compared using the Mann-Whitney U test. Results: Overall, 355 lesions (71 lesions with 5 different reconstructions each) were evaluated. The 20-min reconstruction with 100% injected dose showed the best results in all categories. For general image quality and artifacts, image sharpness, and noise, the reconstructions with a simulated dose of 20% and 10% were significantly better than the 2-min reconstructions (P ≤ 0.001). Furthermore, 20%, 10%, and 5% reconstructions did not yield results different from those of the 2-min reconstruction for detectability of the primary lesion. For 10% of the injected dose, a calculated mean dose of 22.6 ± 5.5 MBq (range, 17.9-36.9 MBq) would have been applied, resulting in an estimated whole-body radiation burden of 0.5 ± 0.1 mSv (range, 0.4-0.7 mSv). Conclusion: Ten percent of the standard dose of 18F-FDG (reduction of ≤90%) results in clinically acceptable PET image quality in time-of-flight PET/MRI. The calculated radiation exposure would be comparable to the effective dose of a single digital mammogram. A reduction of radiation burden to this level might justify partial-body examinations with PET/MRI for dedicated indications.
Collapse
Affiliation(s)
- Bert-Ram Sah
- Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland .,Department of Cancer Imaging, King`s College London, London, United Kingdom.,Department of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich, Switzerland.,University of Zurich, Zurich, Switzerland
| | - Soleen Ghafoor
- Department of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich, Switzerland.,University of Zurich, Zurich, Switzerland
| | - Irene A Burger
- Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland.,University of Zurich, Zurich, Switzerland.,Cancer Center Zurich, Zurich, Switzerland
| | - Edwin E G W Ter Voert
- Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland.,University of Zurich, Zurich, Switzerland
| | - Tetsuro Sekine
- Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland
| | - Gaspar Delso
- Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland.,GE Healthcare, Waukesha, Wisconsin
| | - Martin Huellner
- Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland.,University of Zurich, Zurich, Switzerland
| | - Konstantin J Dedes
- Cancer Center Zurich, Zurich, Switzerland.,Department of Gynaecology, University Hospital of Zurich, Zurich, Switzerland
| | - Andreas Boss
- Department of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich, Switzerland.,University of Zurich, Zurich, Switzerland
| | - Patrick Veit-Haibach
- Department of Nuclear Medicine, University Hospital of Zurich, Zurich, Switzerland.,Department of Diagnostic and Interventional Radiology, University Hospital of Zurich, Zurich, Switzerland.,University of Zurich, Zurich, Switzerland.,Joint Department of Medical Imaging, University Health Network, Toronto, Ontario, Canada; and.,University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
23
|
Yanai A, Itoh M, Hirakawa H, Yanai K, Tashiro M, Harada R, Yoshikawa A, Yamamoto S, Ohuchi N, Ishida T. Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer. TOHOKU J EXP MED 2018; 245:13-19. [PMID: 29731479 DOI: 10.1620/tjem.245.13] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Positron emission mammography (PEM) has higher detection sensitivity for breast cancer compared with whole-body positron emission tomography (PET) due to higher spatial resolution. We have developed a new PEM device with high resolution over a wide field of view. This PEM device comprises novel scintillation crystals, praseodymium-doped lutetium aluminum garnet (Pr:LuAG). In the present study, the clinical use of the newly developed PEM for the detection of small breast cancer was compared with that of the conventional PET-computed tomography (PET/CT). Eighty-two patients with breast cancer less than 20 mm (UICC T1) participated in this study, including 23 patients with T1a or T1b breast cancer (less than 10 mm). Histologically-proved lesions were examined by PET/CT and PEM on the same day after injection of [18F]fluoro-2-deoxy-2-fluoro-D-glucose ([18F]FDG), a marker of glycolytic activity. The newly developed PEM showed better sensitivity of cancer detection compared with PET/CT especially in case of the small T1a or T1b lesions. Moreover, when the conventional PET/CT and new PEM were combined, the detection sensitivity with [18F]FDG molecular imaging for T1 (N = 82) and T1a plus T1b breast cancer (N = 23) were 90% and 70%, respectively. The uptake of [18F]FDG was proportional to the histological malignancy of breast cancer. Using the newly-developed PEM with [18F]FDG, we are able to identify and characterize exactly the small breast tumors less than 10 mm in combination with the conventional PET/CT. These data indicate that PEM and PET/CT are synergic and complementary for the detection of small breast cancer.
Collapse
Affiliation(s)
- Ai Yanai
- Department of Surgical Oncology, Tohoku University Graduate School of Medicine.,Department of Pharmacology, Tohoku University Graduate School of Medicine
| | - Masatoshi Itoh
- Sendai Medical Imaging Center.,Cyclotron Radioisotope Center (CYRIC), Tohoku University
| | | | - Kazuhiko Yanai
- Cyclotron Radioisotope Center (CYRIC), Tohoku University.,Department of Pharmacology, Tohoku University Graduate School of Medicine
| | - Manabu Tashiro
- Cyclotron Radioisotope Center (CYRIC), Tohoku University
| | - Ryuichi Harada
- Department of Pharmacology, Tohoku University Graduate School of Medicine
| | | | | | - Noriaki Ohuchi
- Department of Surgical Oncology, Tohoku University Graduate School of Medicine
| | - Takanori Ishida
- Department of Surgical Oncology, Tohoku University Graduate School of Medicine
| |
Collapse
|
24
|
Heller SL, Heacock L, Moy L. Developments in Breast Imaging: Update on New and Evolving MR Imaging and Molecular Imaging Techniques. Magn Reson Imaging Clin N Am 2018; 26:247-258. [PMID: 29622129 DOI: 10.1016/j.mric.2017.12.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
This article reviews new developments in breast imaging. There is growing interest in creating a shorter, less expensive MR protocol with broader applicability. There is an increasing focus on and consideration for the additive impact that functional analysis of breast pathology have on identifying and characterizing lesions. These developments apply to MR imaging and molecular imaging. This article reviews evolving breast imaging techniques with attention to strengths, weaknesses, and applications of these approaches. We aim to give the reader familiarity with the state of current developments in the field and to increase awareness of what to expect in breast imaging.
Collapse
Affiliation(s)
- Samantha Lynn Heller
- NYU School of Medicine, NYU Laura and Isaac Perlmutter Cancer Center, 3rd Floor, New York, NY 10016, USA
| | - Laura Heacock
- NYU School of Medicine, NYU Laura and Isaac Perlmutter Cancer Center, 3rd Floor, New York, NY 10016, USA
| | - Linda Moy
- NYU School of Medicine, NYU Laura and Isaac Perlmutter Cancer Center, 3rd Floor, New York, NY 10016, USA.
| |
Collapse
|
25
|
Niell BL, Freer PE, Weinfurtner RJ, Arleo EK, Drukteinis JS. Screening for Breast Cancer. Radiol Clin North Am 2017; 55:1145-1162. [DOI: 10.1016/j.rcl.2017.06.004] [Citation(s) in RCA: 65] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Schmitz J, Schwab J, Schwenck J, Chen Q, Quintanilla-Martinez L, Hahn M, Wietek B, Schwenzer N, Staebler A, Kohlhofer U, Aina OH, Hubbard NE, Reischl G, Borowsky AD, Brucker S, Nikolaou K, la Fougère C, Cardiff RD, Pichler BJ, Schmid AM. Decoding Intratumoral Heterogeneity of Breast Cancer by Multiparametric In Vivo Imaging: A Translational Study. Cancer Res 2016; 76:5512-22. [PMID: 27466286 PMCID: PMC5414858 DOI: 10.1158/0008-5472.can-15-0642] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2015] [Accepted: 07/06/2016] [Indexed: 01/20/2023]
Abstract
Differential diagnosis and therapy of heterogeneous breast tumors poses a major clinical challenge. To address the need for a comprehensive, noninvasive strategy to define the molecular and functional profiles of tumors in vivo, we investigated a novel combination of metabolic PET and diffusion-weighted (DW)-MRI in the polyoma virus middle T antigen transgenic mouse model of breast cancer. The implementation of a voxelwise analysis for the clustering of intra- and intertumoral heterogeneity in this model resulted in a multiparametric profile based on [(18)F]Fluorodeoxyglucose ([(18)F]FDG)-PET and DW-MRI, which identified three distinct tumor phenotypes in vivo, including solid acinar, and solid nodular malignancies as well as cystic hyperplasia. To evaluate the feasibility of this approach for clinical use, we examined estrogen receptor-positive and progesterone receptor-positive breast tumors from five patient cases using DW-MRI and [(18)F]FDG-PET in a simultaneous PET/MRI system. The postsurgical in vivo PET/MRI data were correlated to whole-slide histology using the latter traditional diagnostic standard to define phenotype. By this approach, we showed how molecular, structural (microscopic, anatomic), and functional information could be simultaneously obtained noninvasively to identify precancerous and malignant subtypes within heterogeneous tumors. Combined with an automatized analysis, our results suggest that multiparametric molecular and functional imaging may be capable of providing comprehensive tumor profiling for noninvasive cancer diagnostics. Cancer Res; 76(18); 5512-22. ©2016 AACR.
Collapse
Affiliation(s)
- Jennifer Schmitz
- Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Julian Schwab
- Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Johannes Schwenck
- Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University Tuebingen, Tuebingen, Germany. Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Qian Chen
- Center for Comparative Medicine, University of California, Davis, California
| | | | - Markus Hahn
- Department of Women's Health, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Beate Wietek
- Department of Diagnostic and Interventional Radiology, Eberhard Karls University, Tuebingen, Germany
| | - Nina Schwenzer
- Department of Diagnostic and Interventional Radiology, Eberhard Karls University, Tuebingen, Germany
| | - Annette Staebler
- Department of Pathology, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Ursula Kohlhofer
- Department of Pathology, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Olulanu H Aina
- Center for Comparative Medicine, University of California, Davis, California
| | - Neil E Hubbard
- Center for Comparative Medicine, University of California, Davis, California
| | - Gerald Reischl
- Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | | | - Sara Brucker
- Department of Women's Health, Eberhard Karls University Tuebingen, Tuebingen, Germany
| | - Konstantin Nikolaou
- Department of Diagnostic and Interventional Radiology, Eberhard Karls University, Tuebingen, Germany. German Cancer Consortium, German Cancer Research Center, Tuebingen, Germany
| | - Christian la Fougère
- Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard Karls University Tuebingen, Tuebingen, Germany. German Cancer Consortium, German Cancer Research Center, Tuebingen, Germany
| | - Robert D Cardiff
- Center for Comparative Medicine, University of California, Davis, California
| | - Bernd J Pichler
- Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University Tuebingen, Tuebingen, Germany. German Cancer Consortium, German Cancer Research Center, Tuebingen, Germany
| | - Andreas M Schmid
- Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, Eberhard Karls University Tuebingen, Tuebingen, Germany.
| |
Collapse
|
27
|
Bitencourt AGV, Lima ENP, Macedo BRC, Conrado JLFA, Marques EF, Chojniak R. Can positron emission mammography help to identify clinically significant breast cancer in women with suspicious calcifications on mammography? Eur Radiol 2016; 27:1893-1900. [PMID: 27585658 DOI: 10.1007/s00330-016-4576-z] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2016] [Revised: 07/24/2016] [Accepted: 08/22/2016] [Indexed: 01/21/2023]
Abstract
OBJECTIVE To evaluate the diagnostic accuracy of positron emission mammography (PEM) for identifying malignant lesions in patients with suspicious microcalcifications detected on mammography. METHODS A prospective, single-centre study that evaluated 40 patients with suspicious calcifications at mammography and indication for percutaneous or surgical biopsy, with mean age of 56.4 years (range: 28-81 years). Patients who agreed to participate in the study underwent PEM with 18F-fluorodeoxyglucose before the final histological evaluation. PEM findings were compared with mammography and histological findings. RESULTS Most calcifications (n = 34; 85.0 %) were classified as BIRADS 4. On histology, there were 25 (62.5 %) benign and 15 (37.5 %) malignant lesions, including 11 (27.5 %) ductal carcinoma in situ (DCIS) and 4 (10 %) invasive carcinomas. On subjective analysis, PEM was positive in 15 cases (37.5 %) and most of these cases (n = 14; 93.3 %) were confirmed as malignant on histology. There was one false-positive result, which corresponded to a fibroadenoma, and one false negative, which corresponded to an intermediate-grade DCIS. PEM had a sensitivity of 93.3 %, specificity of 96.0 % and accuracy of 95 %. CONCLUSION PEM was able to identify all invasive carcinomas and high-grade DCIS (nuclear grade 3) in the presented sample, suggesting that this method may be useful for further evaluation of patients with suspected microcalcifications. KEY POINTS • Many patients with suspicious microcalcifications at mammography have benign results at biopsy. • PEM may help to identify invasive carcinomas and high-grade DCIS. • Management of patients with suspicious calcifications can be improved.
Collapse
Affiliation(s)
- Almir G V Bitencourt
- A C Camargo Cancer Center-Department of Imaging, R. Prof. Antônio Prudente, 211, São Paulo, SP, Brazil, 01509-010.
| | - Eduardo N P Lima
- A C Camargo Cancer Center-Department of Imaging, R. Prof. Antônio Prudente, 211, São Paulo, SP, Brazil, 01509-010
| | - Bruna R C Macedo
- A C Camargo Cancer Center-Department of Imaging, R. Prof. Antônio Prudente, 211, São Paulo, SP, Brazil, 01509-010
| | - Jorge L F A Conrado
- A C Camargo Cancer Center-Department of Imaging, R. Prof. Antônio Prudente, 211, São Paulo, SP, Brazil, 01509-010
| | - Elvira F Marques
- A C Camargo Cancer Center-Department of Imaging, R. Prof. Antônio Prudente, 211, São Paulo, SP, Brazil, 01509-010
| | - Rubens Chojniak
- A C Camargo Cancer Center-Department of Imaging, R. Prof. Antônio Prudente, 211, São Paulo, SP, Brazil, 01509-010
| |
Collapse
|
28
|
PEM or MBI? Ann Nucl Med 2016; 30:450-1. [PMID: 27194162 PMCID: PMC4925681 DOI: 10.1007/s12149-016-1077-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Accepted: 04/06/2016] [Indexed: 11/17/2022]
|
29
|
Reply to ‘PEM or MBI?’. Ann Nucl Med 2016; 30:452. [DOI: 10.1007/s12149-016-1082-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2016] [Accepted: 05/09/2016] [Indexed: 10/21/2022]
|
30
|
Uematsu T. The need for supplemental breast cancer screening modalities: a perspective of population-based breast cancer screening programs in Japan. Breast Cancer 2016; 24:26-31. [PMID: 27259342 DOI: 10.1007/s12282-016-0707-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Accepted: 05/22/2016] [Indexed: 11/25/2022]
Abstract
PURPOSE This article discusses possible supplemental breast cancer screening modalities for younger women with dense breasts from a perspective of population-based breast cancer screening program in Japan. CONCLUSION Supplemental breast cancer screening modalities have been proposed to increase the sensitivity and detection rates of early stage breast cancer in women with dense breasts; however, there are no global guidelines that recommend the use of supplemental breast cancer screening modalities in such women. Also, no criterion standard exists for breast density assessment. Based on the current situation of breast imaging in Japan, the possible supplemental breast cancer screening modalities are ultrasonography, digital breast tomosynthesis, and breast magnetic resonance imaging. An appropriate population-based breast cancer screening program based on the balance between cost and benefit should be a high priority. Further research based on evidence-based medicine is encouraged. It is very important that the ethnicity, workforce, workflow, and resources for breast cancer screening in each country should be considered when considering supplemental breast cancer screening modalities for women with dense breasts.
Collapse
Affiliation(s)
- Takayoshi Uematsu
- Breast Imaging and Breast Intervention Section, Shizuoka Cancer Center Hospital, Naga-izumi, Shizuoka, 411-8777, Japan.
| |
Collapse
|